Clinical Trial Update: A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) [Phase 2]

View source ↗

Summary

A Phase 2 study of axatilimab at three doses in chronic graft-versus-host disease has posted results; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-10